RGC Share Price Performance
US$29.17
29.05 (24,102.25%)
1.3k% overvalued intrinsic discount
US$2.15
Fair Value
Price US$29.17
unknown US$2.15
Fair ValueUS$2.15
Share Pricen/a
Regencell Bioscience Holdings Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
RGC Community Narratives
UN
Fair Value US$2.15 1.3k% overvalued intrinsic discount
Regencell Bioscience Holdings Ltd. (RGC) The TCM Biotech Lottery Ticket: High Hopes and Extreme Volatility
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Regencell Bioscience Holdings Ltd. (RGC) The TCM Biotech Lottery Ticket: High Hopes and Extreme Volatility
If you're looking for a stock that perfectly embodies the wild, speculative side of the market for your viewers, Regencell Bioscience (RGC) is it. As of late February 2026, this Hong Kong-headquartered, early-stage bioscience company is trading around $29.17 , following a period of mind-bending volatility where the stock surged thousands of percent over the past year.Read more
4
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Trending Discussion
Recently Updated Narratives
UN
Regencell Bioscience Holdings Ltd. (RGC) The TCM Biotech Lottery Ticket: High Hopes and Extreme Volatility
Fair Value: US$2.15 1.3k% overvalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Regencell Bioscience Holdings Limited Key Details
About RGC
- Founded
- 2014
- Employees
- 10
- CEO
- WebsiteView website
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
